Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, today announced that it has partnered with Thermo Fisher Scientific to evaluate a diagnostic to assess the risk of developing complications from overimmunosuppression in kidney transplant recipients based on a metabolomics signature discovered via Olaris’ platform.
Elizabeth O’Day, CEO and Founder of Olaris, was a MassNextGen awardee in 2018. MassNextGen aims to ensure greater gender parity in the next generation of life science entrepreneurs. Olaris, Inc. also participates in the MLSC’s Internship Challenge, a program that enables small companies to hire paid interns by connecting them with candidates through an online platform and reimbursing them for intern stipends.